文献速递神经肌肉病

他莫昔芬在杜氏肌营养不良男孩中的安全性和有效性(TAMDMD):一项多中心、随机、双盲、安慰剂对照的3期试验

Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Neurol · 2023-01-01

这项多中心、随机、双盲、安慰剂对照的3期试验在7个欧洲国家的12个中心纳入82名6.5-12.0岁、接受稳定糖皮质激素治疗的可行走杜氏肌营养不良男孩,随机分配至每日口服20 mg他莫昔芬组(40人)或匹配安慰剂组(38人),治疗48周。主要疗效终点(运动功能量表D1域评分从基线至第48周的变化)在他莫昔芬组(-3.05%,95%CI -7.02至0.91)与安慰剂组(-6.15%,95%CI -9.19至-3.11)之间无显著差异(差异2.90%,95%CI -3.02至8.82,p=0.33)。他莫昔芬安全且耐受良好,但作者认为因临床证据不足,目前不能推荐他莫昔芬作为杜氏肌营养不良男孩的日常临床治疗选择。

要点

  • 他莫昔芬组与安慰剂组主要疗效终点无显著差异(差异2.90%,95%CI -3.02至8.82,p=0.33)。
  • 他莫昔芬安全且耐受良好,严重不良事件仅2例(他莫昔芬组跌倒1例,安慰剂组惊恐发作1例)。
  • 作者认为因临床证据不足,目前不能推荐他莫昔芬用于杜氏肌营养不良男孩的日常临床治疗。

核心结论

  • 他莫昔芬安全且耐受良好,但主要疗效终点在组间无差异。
  • 他莫昔芬组较安慰剂组提示运动功能丧失所致的疾病进展更慢,但结局指标的差异既无临床意义也无统计学意义。
  • 由于临床证据不足,目前不能推荐他莫昔芬作为杜氏肌营养不良男孩的日常临床治疗选择。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照的3期试验,在7个欧洲国家的12个研究中心进行。
  • 纳入6.5-12.0岁、基因确诊杜氏肌营养不良且接受稳定糖皮质激素治疗超过6个月的可行走男孩,按1:1随机分配至每日口服20 mg他莫昔芬组或匹配安慰剂组,按中心和糖皮质激素摄入分层。
  • 主要疗效终点为意图治疗人群中运动功能量表D1域评分从基线至第48周的变化。
  • 2018年5月24日至2020年10月14日筛查95名男孩,82名符合纳入标准并初始入组;3名在随机化前因白内障诊断或撤回知情同意被排除,另1名分配至安慰剂组的男孩未开始治疗;最终意图治疗人群为他莫昔芬组40人、安慰剂组38人。

主要发现

  • 主要疗效终点:他莫昔芬组-3.05%(95%CI -7.02至0.91) vs 安慰剂组-6.15%(95%CI -9.19至-3.11),差异2.90%(95%CI -3.02至8.82,p=0.33),无显著差异。
  • 严重不良事件2例:他莫昔芬组1例跌倒,安慰剂组1例惊恐发作;无死亡或危及生命的严重不良事件。
  • 病毒性感染是最常见的不良事件。

临床怎么用

  • 作者认为因临床证据不足,目前不能推荐他莫昔芬用于杜氏肌营养不良男孩的日常临床治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug repurposing could provide novel treatment options for Duchenne muscular dystrophy. Because tamoxifen-an oestrogen receptor regulator-reduced signs of muscular pathology in a Duchenne muscular dystrophy mouse model, we aimed to assess the safety and efficacy of tamoxifen in humans as an adjunct to corticosteroid therapy over a period of 48 weeks. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial at 12 study centres in seven European countries. We enrolled ambulant boys aged 6·5-12·0 years with a genetically confirmed diagnosis of Duchenne muscular dystrophy and who were on stable corticosteroid treatment for more than 6 months. Exclusion criteria included ophthalmological disorders, including cataracts, and haematological disorders. We randomly assigned (1:1) participants using an online randomisation tool to either 20 mg tamoxifen orally per day or matched placebo, stratified by centre and corticosteroid intake. Participants, caregivers, and clinical investigators were masked to treatment assignments. Tamoxifen was taken in addition to standard care with corticosteroids, and participants attended study visits for examinations every 12 weeks. The primary efficacy outcome was the change from baseline to week 48 in scores on the D1 domain of the Motor Function Measure in the intention-to-treat population (defined as all patients who fulfilled the inclusion criteria and began treatment). This study is registered with ClinicalTrials.gov (NCT03354039) and is completed. FINDINGS: Between May 24, 2018, and Oct 14, 2020, 95 boys were screened for inclusion, and 82 met inclusion criteria and were initially enrolled into the study. Three boys were excluded after initial screening due to cataract diagnosis or revoked consent directly after screening, but before randomisation. A further boy assigned to the placebo group did not begin treatment. Therefore, 40 individuals assigned tamoxifen and 38 allocated placebo were included in the intention-to-treat population. The primary efficacy outcome did not differ significantly between tamoxifen (-3·05%, 95% CI -7·02 to 0·91) and placebo (-6·15%, -9·19 to -3·11; 2·90% difference, -3·02 to 8·82, p=0·33). Severe adverse events occurred in two participants: one participant who received tamoxifen had a fall, and one who received placebo suffered a panic attack. No deaths or life-threatening serious adverse events occurred. Viral infections were the most common adverse events. INTERPRETATION: Tamoxifen was safe and well tolerated, but no difference between groups was reported for the primary efficacy endpoint. Slower disease progression, defined by loss of motor function over time, was indicated in the tamoxifen group compared with the placebo group, but differences in outcome measures were neither clinically nor statistically significant. Currently, we cannot recommend the use of tamoxifen in daily clinical practice as a treatment option for boys with Duchenne muscular dystrophy due to insufficient clinical evidence. FUNDING: Thomi Hopf Foundation, ERA-Net, Swiss National Science Foundation, Duchenne UK, Joining Jack, Duchenne Parent Project, Duchenne Parent Project Spain, Fondation Suisse de Recherche sur les Maladies Musculaires, Association Monegasque contre les Myopathies.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Henzi BC, Schmidt S, Nagy S, et al. Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2023. PMID: 37739572. doi:10.1016/S1474-4422(23)00285-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。